Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | FDPS | P14324 | 3/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181209 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL10803629 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| Octane SCHEMBL1329752 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL7451309 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL10843071 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL6246199 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL9342830 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL9206465 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL16209852 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 | |
| SCHEMBL10841356 | 1.00 | TSHR (0.50) | TSHRTHRBLMNADNM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025052309-A1 | A PROCESS FOR OBTAINING A PURIFIED PSYCHOACTIVE ALKALOID | PSYENCE UK GROUP LTD (GB) | 2025-03-13 | — | — | WO | claimed |
| US-6562968-B2 | Preparing sample by dissolving tetrodotoxin in a weak organic acid; applying tetrodotoxin solution to a chromatography column comprising an octyldecylsilane stationary phase and chromatographically separating sample using mobile phase | NANNING MAPLE LEAF PHARMACEUTICAL CO., LTD. (CN) | 2003-05-13 | — | — | US | claimed |
| US-20020099226-A1 | Method of purifying tetrodotoxin | WEX MEDICAL LIMITED (HK) | 2002-07-25 | — | — | US | claimed |
| US-20020086997-A1 | Method of isolating anhydro-tetrodotoxin | NANNING MAPLE LEAF PHARMACEUTICAL CO., LTD. (CN) | 2002-07-04 | — | — | US | claimed |
| WO-2002042308-A1 | A METHOD OF PURIFYING TETRODOTOXIN | NANNING MAPLE LEAF PHARMACEUTICAL CO., LTD. (CN) | 2002-05-30 | — | — | WO | claimed |
| WO-2025052309-A1 | A PROCESS FOR OBTAINING A PURIFIED PSYCHOACTIVE ALKALOID | PSYENCE UK GROUP LTD (GB) | 2025-03-13 | — | — | WO | disclosed |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| US-20240059663-A1 | Facile Purification of Cannabinoid Acids | FINLEY MATTHEW HAVIS (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4263515-A1 | FACILE PURIFICATION OF CANNABINOID ACIDS | Finley, Matthew Havis (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4083053-A1 | METHOD FOR ICATIBANT PREPARATION | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022133362-A1 | FACILE PURIFICATION OF CANNABINOID ACIDS | FINLEY MATTHEW HAVIS (US) | 2022-06-23 | — | — | WO | disclosed |
| US-9149793-B2 | Carbon composite materials for separations | UNITED SCIENCE, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-6228595-B1 | OLIGONUCLEOTIDES OF SPECFIC NUCLEOTIDE SEQUENCES; FOR SENSITIVE, QUANTITATIVE, AUTOMATABLE ASSAY | G.D. SEARLE & CO. | 2001-05-08 | — | — | US | disclosed |
| US-6127117-A | OLIGONUCLEOTIDES WHICH DETECT EXPRESSION OF NUCLEOTIDE SEQUENCES THAT CODE ISOENZYMES OF ENZYMATIC PROTEINS; FOR DETECTING CHEMICAL INDUCTION OF ENZYME EXPRESSION; FOR EVALUTING THE EFFECTS OF XENOBIOTICS ON GENE EXPRESSION | G. D. SEARLE & CO. (US) | 2000-10-03 | — | — | US | disclosed |
| WO-1997043448-A2 | ANALYSIS OF EXPRESSION OF RAT CYTOCHROME P450 ISOENZYMES AND PHASE II CONJUGATING ENZYMES | G.D. SEARLE & CO. (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0600213-A1 | Field portable liquid chromatographic system | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-06-08 | — | — | EP | disclosed |
| US-5317087-A | Purification of the IL-2 receptor | IMMUNEX CORPORATION (US) | 1994-05-31 | — | — | US | disclosed |
| EP-0162699-B1 | INTERLEUKIN-2 RECEPTOR AND DNA ENCODED THEREFOR AND THEIR PREPARATION | IMMUNEX CORPORATION (US) | 1991-11-21 | — | — | EP | disclosed |
| EP-0162699-A2 | Interleukin-2 receptor and DNA encoded therefor and their preparation | IMMUNEX CORPORATION (US) | 1985-11-27 | — | — | EP | disclosed |
| US-4326940-A | Automatic analyzer and control system for electroplating baths | ROHCO INCORPORATED (US) | 1982-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099226-A1 | Method of purifying tetrodotoxin | TMSB4X, INA, LTA | TSHR 310/4885THRB 315/4885LMNA 2006/4885 |
| US-20020086997-A1 | Method of isolating anhydro-tetrodotoxin | TREH, DOHH, INA | TSHR 104/4885THRB 105/4885LMNA 2868/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | TSHR 1312/4885THRB 914/4885LMNA 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.